Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Active, not recruiting · Phase 2 · NCT06122779
Conditions: Heart Failure
At a glance
- Research payments reported, 2025
- $63,007
- U.S. investigators named
- 24
- Sites paid
- 22
- Planned or actual enrollment
- 227
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986435 (drug), Placebo (other)
- Dates
- Started 2023-11-07; completion 2026-12-14
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
From ClinicalTrials.gov, last updated 2026-07-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $63,007 in research payments for this study in 2025 (22 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pankaj Arora, M.D. Cardiology · Birmingham, AL
- Ravi A. Patel Student in an Organized Health Care Education/Training Program · Los Angeles, CA
- Mchale O. Anderson, MD Cardiology · Golden, CO
- Maria M. Almanzar, M.D. Pediatrics · Miami Lakes, FL
- Sander Fernandez, M.D. Family Medicine · Miami, FL
- Nima Taghipour Cardiology · Jacksonville, FL
- Omar E. Wever-pinzon, M.D. Heart Failure & Transplant Cardiology · Miami, FL
- Suhail H. Khadra, MD Single Specialty Group · Munster, IN
- Ashwin K. Ravichandran, MD Heart Failure & Transplant Cardiology · Indianapolis, IN
- Ambarish Pandey, MBBS Cardiology · Ann Arbor, MI
- Harvey Serota, M.D. Interventional Cardiology · Saint Louis, MO
- Marat Fudim, M.D. Cardiology · Durham, NC
- Donald C. Haas, MD Heart Failure & Transplant Cardiology · Lawrenceville, NJ
- Olakunle O. Akinboboye, MD MPH Internal Medicine · Laurelton, NY
- Shudhanshu Alishetti, M.D. Heart Failure & Transplant Cardiology · Brooklyn, NY
- Christopher Cove, MD Interventional Cardiology · Rochester, NY
- Parag Goyal, M.D. Heart Failure & Transplant Cardiology · New York, NY
- Vishal Y. Parikh, M.D. Cardiology · Rochester, NY
- Eugene Pashkovetsky, M.D. Cardiology · Albany, NY
- Kumudha Ramasubbu, MD Cardiology · Brooklyn, NY
- Naeem K. Tahirkheli, M.D. Interventional Cardiology · Oklahoma City, OK
- Jonathan Ginns, MBBS MD Cardiology · Austin, TX
- Amin H. Karim, M.D. Cardiology · Houston, TX
- Katherine T. Tran, OD Optometrists · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Meeting Protocol Incorporated $11,036
- Chicago Medical Research, Llc $5,692
- Main Heart Clinic $4,551
- Saint Louis Heart and Vascular, PC $3,997
- Ascension Medical Group Saint Vincent Indianapolis Cardiology $3,387
- University of Texas Southwestern Medical Center $3,288
- University of Alabama Hospital, AL $3,261
- Bluhm Cardiovascular Institute at Northwestern Medicine $3,254
- South Oklahoma Heart Research $2,748
- Weill Cornell Medicine $2,303
- Ascension St Vincent's Riverside, FL $2,085
- Capital Cardiology Associates $1,992
- Colorado Heart and Vascular - Lakewood $1,878
- Infinite Clinical Research $1,811
- Strong Memorial Hospital, NY $1,538
- New York-Presbyterian Hospital, NY $1,536
- Austin Heart Central at The Heart Hospital of Austin $1,527
- Queens Heart Institute $1,524
- University of Miami Fl Miller School of Medicine -1120 Northwest 14th St $1,411
- Abington Memorial Hospital $1,404
- Duke Cardiology Consult Clinic $1,400
- Rochester General Hospital - Center for Clinical Research $1,384
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.